Physician profile
Mark A Wainwright
NPI 1811970502
$15,954.44
in general payments reported to CMS, 2019-2025
27 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,674 · 2020: $192 · 2021: $201 · 2022: $9,816 · 2023: $3,671 · 2024: $139 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,070.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,643.15 | 2022-2023 | Davinci Xi, Da Vinci Surgical System |
| Medical Device Business Services, INC. | $1,331.97 | 2019 | |
| Abbvie INC. | $561.45 | 2019-2025 | Botox, Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $399.42 | 2020-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $288.51 | 2019-2025 | |
| Exeltis, USA INC. | $113.52 | 2021-2024 | Slynd |
| Avion Pharmaceuticals | $91.81 | 2019-2022 | |
| Pfizer INC. | $91.08 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $59.12 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $45.13 | 2023 | Myfembree |
| Shield Therapeutics INC | $38.15 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $30.27 | 2023-2024 | Veozah |
| Myovant Sciences INC. | $30.13 | 2021-2022 | |
| Duchesnay USA Incorporated | $28.07 | 2019 | |
| Organon LLC | $26.06 | 2021-2025 | Nexplanon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $23.15 | 2019 | |
| Mylan Pharmaceuticals INC. | $15.90 | 2022 | |
| Baxter Healthcare | $15.36 | 2021 | |
| Conmed Corporation | $15.22 | 2023 | Airseal |
| Glaxosmithkline, LLC. | $14.98 | 2023 | Bexsero, Rotarix, Pediarix |
| Agile Therapeutics, INC. | $14.75 | 2023 | Twirla |
| Millicent US INC | $14.08 | 2025 | Femlyv |
| Coopersurgical, INC. | $13.98 | 2022 | |
| Coloplast Corp | $13.52 | 2023 | Altis |
| Therapeuticsmd, INC. | $12.14 | 2020 | |
| Evofem Biosciences, INC. | $11.85 | 2021 | |
| Allergan, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wainwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.